Scientists involved in human disease research are increasingly mindful of the investments of time and resources required in the design and execution of their studies. Regardless of the experimental objectives or techniques applied, samples obtained for clinical and translational research are precious. Particularly with complex, multiphase studies, where portions of samples may be shared among multiple researchers within a lab or in collaborating laboratories, the importance of ensuring sample integrity and quality from sample acquisition to final data analysis is a shared concern.
Implementation of a standardized genotyping workflow to confirm the identity and quality of each sample prior to analysis represents an ideal solution to maximize the integrity of study results.
New!The Advanta™ Sample ID Genotyping Panel is a 96-SNP genotyping assay that enables sample identification and quality assessment. Leveraging Fluidigm microfluidic technology, the Advanta Sample ID Genotyping Panel workflow offers a number of additional benefits to sample identification, including decreased hands-on time and significant cost savings compared to traditional qPCR methods.
Analyze single-cell gene expression with real-time PCR, industry-leading flexibility and consistently high-quality results on the Biomark™ HD system.
Advanta™ Sample ID Genotyping Panel
Confidently manage sample identity and quality throughout the sample journey with a powerful genotyping panel containing 96 unique single-nucleotide polymorphism (SNP) variants, including 80 synonymous human variants located in exonic regions, 10 quality assessment variants, and 6 gender-confirming variants.
SNP Trace™ Panel
Ensure accurate sample identification with an authoritative panel of 96 SNPs that determine specific attributes around gender, ancestry or polymorphism across populations.
SNP Type Assays
Leverage a flexible, economical solution for single nucleotide polymorphism (SNP) genotyping with Fluidigm's SNP Type™ assays.
Flaws in the identity and quality of biorepository specimens produce misleading experimental data that cost research labs millions of dollars in wasted resources, and in some cases to erroneous publications that damage reputations. Given the high price of research and the current funding challenges facing many laboratories, there is greater demand on biorepositories to ensure sample integrity. Yet the biobanking process is prone to error.
The chief operating officer of RUCDR Infinite Biologics at Rutgers University looks like he'd be just as comfortable on a Florida golf course as he is analyzing sample datasets. In truth, Andrew Brooks, PhD, is at ease given any opportunity to discuss the benefits of the work he and his team do to advance biobanking standards.
Now more than ever, scientists understand that diseases are population-specific. To support this research, biobanks must increase the variety and number of samples they store. Unfortunately, with more samples come more opportunities for sample identification errors.
The recent Mendelspod podcast series “Garbage In, Garbage Out: A New Look at Biospecimen Quality” was cosponsored by Fluidigm and provides an in-depth look at the dire state of biospecimen quality and the need for regulation and standardization.